{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire Form

  1. In your clinical practice, approximately how many Ca prostate cancer patients do you see every year? *
    2. Patients/Year
  2. In your clinical practice, what is percentage-wise split of prostate cancer patients in following stages? *
    3. Stage I (Early-stage prostate cancer)

    Stage II (Localized prostate cancer)

    Stage III (Locally advanced prostate cancer)

    Stage IV (Metastatic prostate cancer)

  3. In your clinical practice, among all prostate cancer patients what percentage of patients are *
    4. Direct patients
    %
    Referred by other specialty
    %
  4. As per your clinical practice, what percentage of your newly diagnosed prostate cancer patients undergo *
    5. Medical Castration
    %
    Surgical castration
    %
  5. As per your clinical practice, what percentage of newly diagnosed prostate cancer patients (Previously untreated) receive following LhRh (Luteinizing hormone releasing hormone) analogues? *
    6. LhRh Antagonist
    %
    LhRh Agonist
    %
  6. As per your clinical practice, do you prefer LhRh antagonist over agonist in prostate cancer patients with cardiac co-morbidities? *

  7. In your clinical practice, which set of patients you use following LhRh analogues? (Tick mark as appropriate) *
    8. LhRh Analogues High Volume disease Low volume disease Locally advanced prostate cancer Metastatic prostate cancer Gleason score of >7

    LhRh Agonist

    LhRh Antagonist

  8. In your clinical practice, for the treatment of metastatic prostate cancer patients (mHSPC/mCRPC) do you prefer to use Antagonist (Degarelix or Relugolix) as *

  9. Which of the following Leuprolide dosage regimen is used most frequently in your current clinical practice? *

  10. As per your clinical practice, what is the average treatment duration of androgen deprivation therapy (ADT) in following stages of prostate cancer? *
    11. Stage Treatment duration in Months
    Localized prostate cancer

    Locally advanced prostate cancer

    Metastatic prostate cancer

  11. What % of your newly diagnosed metastatic prostate cancer patients, do you get to see with *
    12. Pre-existing Cardiac co-morbidities
    %
    Highly symptomatic disease
    %
    High volume disease
    %
  12. In your clinical practice, do you switch from LhRh agonist to LhRh antagonist or vice versa while treating prostate cancer patients? *

  13. In your clinical practice, what is the percentage-wise split of mCSPC patients as per following stage *
    14. De-Novo mCSPC
    %
    Progressive disease (Locally advanced prostate cancer to mCSPC)
    %
  14. What % of mCSPC patients referred to you are previously treated with abiraterone/enzalutamide? *
    15. %
  15. As per your clinical practice, what is the average duration of PFS in mCSPC patients treated with following therapies in first line setting? *
    16. Abiraterone
    months
    Enzalutamide
    months
  16. In your clinical practice, do you follow any sequential strategy for the management of mCSPC? *

  17. For mCSPC treatment, apart from OS and radiographic PFS, which of the following parameters do you consider for positive clinical outcomes (Tick mark multiple options if you follow the same)

  18. If PSA decline is an important prognostic marker, what kind of PSA reduction would you like to see in your patients?

  19. Upon progression on first line mCSPC therapy, what % of patients: *
    20. Remains in mCSPC stage even after progressing on 1L therapy
    %
    Progress to mCRPC stage
    %
  20. The recent clinical data from TITAN trial shows that, Apalutamide offers rapid, deep & ultra-low PSA reduction that results in survival benefit. Based on this data, would you prefer Apalutamide upfront in mCSPC? *

  21. Among Abiraterone, Enzalutamide, Apalutamide, which molecule would you choose for treating mCSPC patients? *
    22. Molecule name
    If Cost is a concern
    1st Preference
    2nd Preference
    If cost is not a concern
    1st Preference
    2nd Preference
  22. As per your clinical practice, what % of mCSPC patients have high volume disease? *
    23. %
  23. In your clinical practice, what is the percentage-wise split of high volume mCSPC patients receiving following treatments? (Can select multiple options) *

    24. %

    %

    %

    %

    %
  24. If cost is not a concern, what % of your mCSPC patients are fit for taking triplet regimen (ADT+Docetaxel+Darolutamide or Abiraterone acetate)?
    25. %